Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
DUBLIN–(BUSINESS WIRE)–Apr. 16, 2026– Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the......






